SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): November
19, 2008
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements made in this Report that
are not historical facts may constitute forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ
materially from those discussed. Such risks and uncertainties include
but are not limited to those discussed in this report and in our other reports
filed with the Securities and Exchange Commission. Words such as “expects,”
“may,” “will,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and similar expressions identify forward-looking
statements.
Section
7 - Regulation FD
Item
7.01 - Regulation FD Disclosure
Section
9 - Financial Statements and Exhibits
Item
9.01 - Financial Statements and Exhibits
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated November 19, 2008
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIOTIME,
INC.
|
|
|
Date: November
19, 2008
|
By /s/ Steven
A. Seinberg
|
|
Chief
Financial Officer
|
|
3
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated November 19, 2008
|
|
4
Exhibit
99.1
|
BioTime,
Inc.
|
1301
Harbor Bay Parkway
|
|
|
Alameda,
CA 94502
|
||
|
Tel:
510-521-3390
|
||
|
Fax:
510-521-3389
|
||
|
www.biotimeinc.com
|
||
|
www.embryome.com
|
BioTime
CEO Dr. Michael West Announces the Launch of New Products and Discusses the
State of the Stem Cell Industry under the Obama Administration at the Wisconsin
Academy of Sciences, Arts, and Letters
ALAMEDA, CA, November 19, 2008 – BioTime, Inc.
(OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. delivered the keynote
presentation on Wednesday, November 19, at a meeting in Madison, Wisconsin
commemorating the 10th anniversary of the publication describing the first
derivation and culturing of human embryonic stem cells. Dr. West’s presentation
is titled “Opportunities and Challenges of Commercializing Stem Cell Research.”
The Wisconsin Academy, along with University of Wisconsin-Madison and the
Wisconsin Alumni Research Foundation (WARF), hosted the two-day event titled “A
Decade Celebrating Stem Cells: Changing the Face of Medicine Ten Years Later” to
commemorate the publication of the first derivation of human embryonic stem
cells and to examine future trends.
Dr.
West’s presentation included a historical overview of the biotechnology
industry, a description of historical trends in the industry of commercializing
stem cell technology, and a discussion of future opportunities for the field.
Dr. West discussed BioTime’s stem cell research program that is focused on
opportunities for near-term revenues in the development and marketing of
products derived from stem cells.
Dr. West
announced the launch of ten new cell line products and presented data on their
unique properties and potential utility in regenerative medicine. The molecular
markers of these lines are consistent with varied types of human neural crest,
mesodermal, and CNS progenitor cells that have promise for the treatment of
numerous diseases such as cranial-facial, muscular, and neurological disorders.
Information about these cell lines will be available online at www.embryome.com
starting Monday, November 24, 2008, and the cells themselves are now available
for purchase for research purposes only through the same website.
Lastly,
Dr. West discussed federal policies relating to the industry of regenerative
medicine. He announced an open letter to President-Elect Obama signed by 22
scientists and economists (including 19 Nobel laureates), urging the new
Administration to make regenerative medicine, specifically, the cure of human
disease, a national priority, similar in scope to the Kennedy Administration’s
commitment to land a man on the moon within that decade. The text of the letter
to President-Elect Obama is available online at www.biotimeinc.com.
About
BioTime, Inc.
BioTime,
headquartered in Alameda, California, develops blood plasma volume expanders,
blood replacement solutions for hypothermic (low temperature) surgery, organ
preservation solutions, and technology for use in surgery, emergency trauma
treatment and other applications. BioTime's lead product Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corp. under exclusive licensing agreements.
BioTime has recently entered the field
of regenerative medicine through its wholly owned subsidiary Embryome
Sciences, Inc. where it
plans to develop new medical and research products using embryonic stem cell
technology. Additional information about BioTime can be found on the web at
www.biotimeinc.com. Hextend®, PentaLyte®, HetaCool®, EmbryomicsTM, ESpyTM, and ESpanTM, are trademarks of BioTime,
Inc.
Forward-Looking
Statements
Statements
pertaining to future financial and/or operating results, future growth in
research, technology, clinical development and potential opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
BioTime,
Inc.
Judith
Segall
jsegall@biotimemail.com
510-521-3390,
ext. 301
To
receive ongoing BioTime corporate communications, please click on the following
link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0